Sickle Cell Disease Market

Market Overview:

The 7 major Sickle Cell Disease markets reached a value of USD 841.6 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,011.9 Million by 2035, exhibiting a growth rate (CAGR) of 8.2% during 2025-2035.

The sickle cell disease market has been comprehensively analyzed in IMARC's new report titled "Sickle Cell Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". The Sickle Cell Disease market is expected to be driven by a strong pipeline of late-stage drugs that offer a strong efficacy and safety profile. Gene therapies represent the most promising drug candidates, although costly, they are expected to offer patients a cure that avoids a painful and risky bone marrow transplant. Furthermore, diagnosis and treatment rates for sickle cell disease have also improved significantly, creating a positive impact on the market.

Sickle Cell Disease (SCD) is a form of inherited blood disorder. Patients with Sickle cell disease have abnormal hemoglobin. This causes the red blood cells to become hard and sticky and appear like a C-shaped farm tool called a “sickle.” The sickle cells die early, resulting in a constant shortage of red blood cells. Signs and symptoms of sickle cell anemia normally appear around 6 months of age. They vary from one individual to another and may change over time. Common symptoms can include anemia, episodes of pain, swelling of hands and feet, frequent infections, delayed growth or puberty, vision problems, etc. Sickle Cell Disease is a genetic disorder that is present at birth. It is inherited when an individual receives two genes - one from both parents that code for abnormal hemoglobin.

IMARC Group's new report provides an exhaustive analysis of the sickle cell disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for sickle cell disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sickle cell disease market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, Current, and Future Epidemiology Scenario
• Historical, Current, and Future Performance of the Sickle Cell Disease Market
• Historical, Current, and Future Performance of Various Therapeutic Categories in the Sickle Cell Disease Market
• Sales of Various Drugs Across the Sickle Cell Disease Market
• Reimbursement Scenario in the Sickle Cell Disease Market

Competitive Landscape:

This report also provides a detailed analysis of the current Sickle Cell Disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Sickle Cell Disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Sickle Cell Disease market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Sickle Cell Disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Sickle Cell Disease market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of sickle cell disease across the seven major markets?
• What is the number of prevalent cases (2019-2035) of sickle cell disease by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of sickle cell disease by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with sickle cell disease across the seven major markets?
• What is the size of the sickle cell disease patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend sickle cell disease of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for sickle cell disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sickle cell disease market?
• What are the key regulatory events related to the sickle cell disease market?
• What is the structure of clinical trial landscape by status related to the sickle cell disease market?
• What is the structure of clinical trial landscape by phase related to the sickle cell disease market?
• What is the structure of clinical trial landscape by route of administration related to the sickle cell disease market?